CHARACTERISTICS OF WOMEN WITH A FAMILY HISTORY OF OVARIAN-CANCER .2. FOLLICULAR PHASE HORMONE LEVELS

被引:0
|
作者
CRAMER, DW [1 ]
BARBIERI, RL [1 ]
MUTO, MG [1 ]
KELLY, A [1 ]
BRUCKS, JP [1 ]
HARLOW, BL [1 ]
机构
[1] BRIGHAM & WOMENS HOSP, DEPT OBSTET & GYNECOL, BOSTON, MA 02115 USA
关键词
OVARIAN CANCER; GONADOTROPINS; CA; 125; FAMILIAL; ESTRADIOL; GALACTOSE-1-PHOSPHATE URIDYLTRANSFERASE;
D O I
10.1002/1097-0142(19940815)74:4<1318::AID-CNCR2820740422>3.0.CO;2-V
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Although there is a basis for linking pituitary or ovarian hormones with experimentally induced ovarian cancer, establishing their role in women is complicated because the usual case-control methods cannot be applied. In this study, hormonal levels in women with a family history of ovarian cancer (FOC) and who are at higher risk for the disease are compared with women without such a history. Methods. The authors studied 106 unrelated women (FOC patients) with at least one primary or two second-degree relatives with ovarian cancer compared with 116 age- and residence-matched controls without a family history of ovarian cancer (FOC control subjects). All women were premenopausal, between the ages of 25 and 49 years, not currently using oral contraceptives, and had blood drawn during the early follicular phase for gonadotropins, estradiol (E(2)), and CA-125. Results. Women with a family history of ovarian cancer and control subjects did not differ significantly in follicle stimulating hormone (FSH) levels, E(2), or CA-125. Patients with a family history of ovarian cancer had significantly lower luteinizing hormone (LH) levels compared with control subjects and produced more E(2) and FSH relative to their level of LH. The ratios of LH to E(2) and LH to FSH were correlated with the enzymatic activity of galactose-1-phosphate uridyl transferase, which was shown previously to differ between FOC patients and control subjects. Conclusion. Lower LH and higher E(2) are reported in women with breast, endometrial, and ovarian cancer (before surgery). The authors speculate that these observations reflect greater LH binding and estradiol production in ovaries at risk for these cancers-the ovarian cortical hyperplasia postulated in older gynecologic literature as the precursor to estrogen dependent neoplasia.
引用
收藏
页码:1318 / 1322
页数:5
相关论文
共 46 条
  • [21] Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
    Metcalfe, Kelly
    Lubinski, Jan
    Lynch, Henry T.
    Ghadirian, Parviz
    Foulkes, William D.
    Kim-Sing, Charmaine
    Neuhausen, Susan
    Tung, Nadine
    Rosen, Barry
    Gronwald, Jacek
    Ainsworth, Peter
    Sweet, Kevin
    Eisen, Andrea
    Sun, Ping
    Narod, Steven A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (24): : 1874 - 1878
  • [22] Elevated early follicular gonadotropin levels in women with unexplained infertility do not provide evidence for disordered gonadotropin-releasing hormone secretion as assessed by luteinizing hormone pulse characteristics
    Randolph, JF
    Ginsburg, KA
    Leach, RE
    Blacker, CM
    Moghissi, KS
    Diamond, MP
    Reame, NE
    FERTILITY AND STERILITY, 2003, 80 (02) : 320 - 327
  • [23] A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center
    Gilpin, CA
    Carson, N
    Hunter, AGW
    CLINICAL GENETICS, 2000, 58 (04) : 299 - 308
  • [24] Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk
    Teixeira, Natalia
    Mourits, Marian J. E.
    Vos, Janet R.
    van der Kolk, Donna M.
    Jansen, Liesbeth
    Oostervvijk, Jan C.
    de Bock, Geertruida H.
    MATURITAS, 2015, 82 (02) : 197 - 202
  • [25] EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL OVARIAN EPITHELIUM AND OVARIAN-CANCER .2. RELATIONSHIP BETWEEN RECEPTOR EXPRESSION AND RESPONSE TO EPIDERMAL GROWTH-FACTOR
    RODRIGUEZ, GC
    BERCHUCK, A
    WHITAKER, RS
    SCHLOSSMAN, D
    CLARKEPEARSON, DL
    BAST, RC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (03) : 745 - 750
  • [26] PHASE-2 TRIAL OF CHRONIC LOW-DOSE ORAL ETOPOSIDE AS SALVAGE THERAPY OF PLATINUM-REFRACTORY OVARIAN-CANCER
    MARKMAN, M
    HAKES, T
    REICHMAN, B
    CURTIN, J
    BARAKAT, R
    RUBIN, S
    JONES, W
    LEWIS, JL
    ALMADRONES, L
    HOSKINS, W
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1992, 119 (01) : 55 - 57
  • [27] Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients
    Singer, Christian F.
    Tan, Yen Y.
    Muhr, Daniela
    Rappaport, Christine
    Gschwantler-Kaulich, Daphne
    Grimm, Christoph
    Polterauer, Stephan
    Pfeiler, Georg
    Berger, Andreas
    Tea, Muy-Kheng M.
    CANCER MEDICINE, 2019, 8 (04): : 1875 - 1881
  • [28] Follicular Phase Endocrine Characteristics during Ovarian Stimulation and GnRH Antagonist Cotreatment for IVF: RCT Comparing recFSH Initiated on Cycle Day 2 or 5
    Blockeel, Christophe
    Sterrenburg, Monique D.
    Broekmans, Frank J.
    Eijkemans, Marinus J. C.
    Smitz, Johan
    Devroey, Paul
    Fauser, Bart C. J. M.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04): : 1122 - 1128
  • [29] Founder BRCA1 and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family history
    Tonin, PN
    Mes-Masson, AM
    Narod, SA
    Ghadirian, P
    Provencher, D
    CLINICAL GENETICS, 1999, 55 (05) : 318 - 324
  • [30] Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer
    Sunar, Veli
    Korkmaz, Vakkas
    Topcu, Vehap
    Cavdarli, Busranur
    Arik, Zafer
    Ozdal, Bulent
    Ustun, Yaprak Engin
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (01) : 84 - 92